We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
New Compounds, Novel Applications Described.
- Authors
Bender, Kenneth J.
- Abstract
The article focuses on the evaluation of psychiatric drugs and products. Agomelatine, a melatonergic compound from Novartis, was evaluated for antidepressant effect and compared to venlafaxine. Bifeprunox from H Lundbeck A/S, Solvay Pharmaceuticals and Wyeth Pharmaceuticals and asenapine from Organon International are seen as possible long-term treatments for schizophrenia. The cholinesterase inhibitor galantamine is revealed to reduce or prevent cognitive impairment on post electroconvulsive therapy (ECT) situations.
- Subjects
PSYCHIATRIC drugs; CLINICAL drug trials; ANTIDEPRESSANTS; CHOLINESTERASE inhibitors; NOVARTIS AG; H. Lundbeck A/S; SOLVAY Pharmaceuticals Inc.; WYETH Pharmaceuticals Inc.
- Publication
Psychiatric Times, 2008, Vol 25, Issue 1, p35
- ISSN
0893-2905
- Publication type
Article